NCT06424639View on ClinicalTrials.gov

Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAA

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

December 31, 2025

Conditions
Aplastic Anemia
Interventions
DRUG

Luspatercept

Luspatercept (dose of 1.0 mg/kg, subcutaneous injection every 3 weeks) Cyclosporine (3-5mg/kg/day)

DRUG

cyclosporine

Cyclosporine (3-5mg/kg/day)

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT06424639 - Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAA | Biotech Hunter | Biotech Hunter